Expanding AmorphOX through strategic collaborations

Pioneering new formulations that deliver value

AmorphOX transforms existing medications into next-generation products with superior bioavailability, stability, and improved patient experience. Reformulating established drugs opens opportunities for new extensions and additional revenue streams. For example, an existing treatment reformulated with AmorphOX can achieve faster absorption and a longer shelf life, creating new commercial opportunities.

Broadening therapeutic reach

Augmenting drug delivery, such as through additional routes, may expand use cases to develop additional indications for new patient groups. Making use of, for example the nasal route of administration, can achieve additional therapeutic benefits, such as the successful prevention of pathogen transmission within airborne diseases.

Rapid onset for critical care

Speed matters in emergencies. The AmorphOX powder dissolves quickly, enabling rapid absorption. This makes it ideal for emergencies, rapid pain relief, and other timesensitive treatments. This positions partner products as best-in-class for fast therapeutic effects.

Patient-centric drug delivery

Convenience drives adherence. AmorphOX® supports needle-free formats like intranasal powders or oral tablets that quickly dissolve, replacing injections with simple, patient-friendly options. This improves comfort and confidence, enables self-administration, and broadens market adoption opportunities.

Efficient manufacturing and distribution, enabled by stability

Exceptional stability removes the need for cold-chain logistics, lowering costs and environmental impact. Room-temperature storage streamlines global distribution and supports reliable, scalable manufacturing.

Extended intellectual property protection

Reformulating with AmorphOX can qualify for new patents, extending exclusivity and securing long-term value. Orexo’s integrated IP strategy ensures robust protection, including multiple patents listed in the FDA’s Orange Book, reinforcing the commercial attractiveness of collaboration.